This study is open to adults with PPF . The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.
Adults aged ≥18 year.
Diagnosis of PPF other than IPF prior to screening or during the screening period.
Clinically significant airways obstruction (Forced Expiratory Volume in One Second (FEV1)/Forced Vital Capacity (FVC) < 0.7) at screening.
In the opinion of the Investigator, other clinically significant pulmonary abnormalities.
Acute ILD exacerbation within 3 months prior to screening and/or during the screening period.
History of malignancy within 5 years prior to screening.